glp 1 alzheimer's disease GLP-1 drugs failed to slow in two big clinical trials Frontiers | GLP-1 and Underlying
Description
In most cases, there is no reason to discontinue GLP-1 treatment unless another specific medical indication arises
No stimulants
For example, a family history of obesity and T2D may be an independent risk factor for obesity and IR in patients with T1D ( Insulin resistance in T1D could also be related to the insulin administration route
Very different experience
Side effects are possible but tend to be milder with microdosing compared to higher doses
